ReviewInternational journal of molecular medicine2026
Contribution of p38 MAPK in liver fibrosis: An overview of mechanisms, signaling pathways, and therapeutic targets (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis is a progressive pathological state characterized by aberrant accumulation of extracellular matrix (ECM), predominantly mediated by activation of hepatic stellate cells (HSCs). If left untreated, this condition can progress to cirrhosis, liver failure, and even hepatocellular carcinoma. As a pivotal constituent of the mitogen‑activated protein kinase (MAPK) superfamily, p38 MAPK orchestrates critical cellular processes, including proliferation, differentiation, and stress responses. The p38 MAPK signaling cascade has been identified as a central orchestrator of the pathogenic mechanisms underlying liver fibrosis, mediating key processes such as HSC activation, ECM remodeling, inflammation, oxidative stress, and apoptosis. Developing novel antifibrotic therapies hinges on a comprehensive elucidation of the functional roles and regulatory mechanisms governing p38 MAPK. The present review aims to provide an exhaustive synthesis of the mechanisms and signaling networks by which p38 MAPK contributes to liver fibrogenesis. Its roles in HSC transformation, interactions with other critical pathways (including NF‑κB, TGF‑β/Smad, JAK/STAT, and PI3K/Akt), and involvement in inflammatory and oxidative responses are explored. Furthermore, the therapeutic potential of targeting p38 MAPK is highlighted by preclinical evidence from pharmacological inhibitors, natural compounds, and traditional medicines that modulate this pathway to attenuate fibrosis. In conclusion, while p38 MAPK represents a promising therapeutic target for liver fibrosis, future research should focus on developing isoform‑specific inhibitors, understanding context‑dependent signaling outcomes, and designing combination therapies to enhance efficacy and minimize off‑target effects. This synthesis aims to bridge current molecular insights with clinical translation, offering a roadmap for future antifibrotic drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.